The effect of developmental changes in adolescence on drug disposition

doi:10.1016/S1054-139X(94)90627-0

Journal of Adolescent Health

Volume 15, Issue 8, December 1994, Pages 612-618

https://doi.org/10.1016/S1054-139X(94)90627-0 Get rights and content

Abstract

Biological and behavioral change occurs throughout the lifespan. The nature and rapidity of change during adolescence is striking. The effects of rapid growth, sexual maturation, and psychological reorganization on pharmacodynamics and pitarmacokinetics must be considered during studies on teenagers.

It is important to consider the large amount of variability in the timing of normal developmental events. The concept of developmental rather than chronological age should be considered. Measurement of organismic and behavioral variables includes whole organism measures such as body height, weight, surface area, body mass index, self-concept, sexual identity/role, and many other behavioral measures. Pubertal development may be assessed by sexual maturity ratings. Bone age may be a particularly useful estimate of developmental status. Biochemical measures include gonadotropin, sex steroids, other hormonal or hormone receptor values.

References (35)

JM Tanner
Growth at Adolescence
(1962)
LD Hammer et al.
Standardized percentile curves of body-mass index for children and adolescents
Am J Dis Child
(1991)
GH Forbes
Nutrition and growth
RE Kreipe
Normal somatic adolescent growth and development
National Center for Health Statistics: Age at menarche, US
Vital Health Stat
(1973)
PA Lee
Normal ages of pubertal events among American males and females
J Adolesc Health Care
(1980)
JM Tanner et al.
The adolescent growth spurt of boys and girls of the Harpenden growth study
Ann Hum Biol
(1976)
National Center for Health Statistics: Growth curves for children, birth-18 years. United States
Vital Health Stat
(1977)
National Center for Health Statistics: Skinfold thickness of youths 12–17 years
Vital Health Stat
(1974)
WE Nelson

BE Clayton et al.

Paediatric chemical pathology. Clinical tests and reference ranges

(1980)

WA Daniel et al.

Iron intake and transferrin saturation in adolescents

Journal of Pediatrics

(1975)

WA Daniel

Hematocrit: Maturity relationship in adolescence

Pediatrics

(1973)

V Abbassi et al.

Thyroid function in relation to age

JD Miller et al.

Daytime pulsatile growth hormone secretion during childhood and adolescence

J Clin Endocr Metab

(1982)

RI Rosenfeld et al.

Relationship of somatomedin-C concentrations to pubertal changes

J Pediatr

(1983)

P Lee

Physiology of puberty

Cited by (17)

Beyond steroids: A systematic review and proposed solutions to managing acute graft-versus-host disease in adolescents and young adults
2022, Blood Reviews
Citation Excerpt :
This personalized approach demonstrates that risk-based interventions can be safely executed in these complex patients, though further studies are warranted [99]. Additional ways to optimize therapy and potentially reduce the risk of acute GVHD in AYAs could include altering the dosages of chemotherapeutic and supportive care drugs, primarily through the use of pharmacokinetic and pharmacogenomic data, as age-related changes in body composition and specific genetic polymorphisms are known to contribute to differences in drug metabolism [100–103]. Pharmacokinetic-guided dosing of busulfan has become the standard-of-care in pediatric HCT, as this approach has demonstrated lower rates of relapse as well as decreased toxicity, including acute GVHD [104].
The outcomes of allogeneic hematopoietic cell transplantation (HCT) in adolescents and young adults (AYAs) with hematologic malignancies have been shown to be poorer when compared to results in children, due to a combination of higher relapse rates and greater treatment-related mortality (TRM). Although differences in relapse risk have been studied extensively, toxicity has been examined and reported less often. In this systematic review, we summarize recently published studies that have examined the differences in rates of TRM and acute graft-versus-host disease (GVHD) in AYAs and children with hematologic malignancies, and attempt to explain why these disparities exist and how they impact outcomes. In addition, we present best practices for management of steroid-refractory GVHD that are likely to improve survival in this patient population. Further, we propose the development of personalized, risk-based approaches for the prevention and treatment of GVHD that incorporate novel platforms and interventions. We believe this individualized approach is likely to reduce toxicity and greatly improve outcomes for this vulnerable population.
Unique Challenges of Hematopoietic Cell Transplantation in Adolescent and Young Adults with Hematologic Malignancies
2018, Biology of Blood and Marrow Transplantation
Citation Excerpt :
During the normal pubertal process, adolescents experience numerous physiological, physical, and psychosocial changes that can affect drug disposition. For example, changes in height and weight, body mass index, body composition, and hormone levels, along with use of oral contraceptives, alcohol, tobacco, and recreational drugs, all may effect pharmacokinetics [54,55]. Changes in body composition include an increase in fat mass in females and a decrease in fat mass and increase in muscle mass for males, changes potentially affecting the volume of distribution as well as plasma drug concentrations [55].
Slow but definite progress has been made in recognizing the differences in disease biology, host factors, and psychosocial issues related to management of hematologic malignancies, including hematopoietic cell transplantation (HCT), in the adolescent and young adult (AYA) population. Improvement in survival rates among AYAs undergoing HCT for hematologic malignancies have paralleled those seen among children and older adults in the contemporary era. However, overall outcomes remain inferior compared with those in children owing largely to higher rates of treatment related mortality and late relapses in AYA HCT recipients. We review the unique issues and challenges facing AYAs with hematologic malignancies undergoing HCT, identify unmet needs and gaps in care, and describe potential strategies to address them. A patient-centric and multidisciplinary approach to AYA HCT care with lifelong follow-up is necessary to ensure long-term health.
The effect of anabolic-androgenic steroids on sexual behavior and reproductive tissues in male rats
1997, Physiology and Behavior
Feinberg, M. J., A. R. Lumia and M. Y. McGinnis. The effect of anabolic-androgenic steroids on sexual behavior and reproductive tissues in male rats. Physiol Behav 62(1) 23–30, 1997.—This study assessed the effects of high doses of anabolic-androgenic steroids (AAS) and their withdrawal on male reproductive behavior and reproductive tissues during development. Prepubertal, peripubertal, and adult male Long Evans rats were divided into 4 groups: 1) Testosterone propionate for 16 weeks (TP), 2) TP for 3 weeks and withdrawn for 13 weeks (TPWL), 3) TP for 16 weeks and withdrawn for 3 weeks (TPWS), 4) propylene glycol (control vehicle) for 16 weeks (PG). As determined by sexual performance and sexual preference tests, administration of high doses of AAS to the peripubertal animals enhanced sexual performance and sexual motivation. There was no significant effect on sexual behavior of the prepubertal animals. High doses of anabolic-androgenic steroids depleted Leydig cell number in the prepubertal and adult rats, but had no effect on the Leydig cell number of the peripubertal animals. After long-term withdrawal from AAS no significant effects on sexual behavior were found. The depletion of Leydig cells that occurred in the prepubertal animals after withdrawal was reversible, while the depletion of the Leydig cells of the adult animals did not return to the control level suggesting a long lasting alteration.
Pharmacokinetic–Pharmacodynamic Modeling of Midazolam in Pediatric Surgery
2023, Pharmaceutics
Influence of Age and Sex on the Pharmacokinetics of Midazolam and the Depth of Sedation in Pediatric Patients Undergoing Minor Surgeries
2023, Pharmaceutics
Why are certain age bands used for children in paediatric studies of medicines?
2021, Archives of Disease in Childhood

View all citing articles on Scopus

View full text

The effect of developmental changes in adolescence on drug disposition

Abstract

Growth at Adolescence

Standardized percentile curves of body-mass index for children and adolescents

Am J Dis Child

Nutrition and growth

Normal somatic adolescent growth and development

National Center for Health Statistics: Age at menarche, US

Vital Health Stat

Normal ages of pubertal events among American males and females

J Adolesc Health Care

The adolescent growth spurt of boys and girls of the Harpenden growth study

Ann Hum Biol

National Center for Health Statistics: Growth curves for children, birth-18 years. United States

Vital Health Stat

National Center for Health Statistics: Skinfold thickness of youths 12–17 years

Vital Health Stat

Paediatric chemical pathology. Clinical tests and reference ranges

Iron intake and transferrin saturation in adolescents

Journal of Pediatrics

Hematocrit: Maturity relationship in adolescence

Pediatrics

Thyroid function in relation to age

Daytime pulsatile growth hormone secretion during childhood and adolescence

J Clin Endocr Metab

Relationship of somatomedin-C concentrations to pubertal changes

J Pediatr

Physiology of puberty